NEUREGEN

NEUREGEN was founded in December 2021 as a biotechnology company dedicated to developing novel gene therapy drugs using its proprietary cell transdifferentiation technology and genetic replacement technology. Established by a closely-knit team of neurobiologists, ophthalmology experts, gene therapy specialists, and veterans from the biopharmaceutical industry, NEUREGEN is committed to transforming emerging cell transdifferentiation technologies into solutions for unmet clinical needs. Currently, centered around cell transdifferentiation technology, NEUREGEN has built a novel gene therapy drug development platform encompassing key technologies such as transdifferentiation factor screening, viral and non-viral vector design, and in vivo and in vitro pharmacodynamic method development, and has filed several critical patents. The company’s product pipeline focuses on neurological diseases, with an emphasis on developing original gene therapy drugs with independent intellectual property rights for blinding eye diseases and difficult-to-treat nervous system tumors.